Please assess the completion status of the following clinical trial:

Trial Title: Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of localized prostate cancer~  * Diagnosed within the past 6 months~ * T1 or T2 disease~ * Gleason score 5-8~ * Prostate-specific antigen no greater than 20 ng/mL~* Radical prostatectomy planned~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* More than 2 years~Hematopoietic~* Hemoglobin greater than 9.0 g/dL~* Platelet count greater than 100,000/mm\^3~* Absolute neutrophil count greater than 1,000/mm\^3~Hepatic~* SGPT and SGOT less than 3 times normal~* Bilirubin less than 3 mg/dL (less than 1.5 times normal) (patients with an elevated bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)~Renal~* Creatinine less than 2.0 mg/dL~Cardiovascular~* No venous thrombosis within the past year~Other~* Patients must use effective barrier contraception~* No other medical condition that would preclude study therapy~* No known soy intolerance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* No concurrent hormonal therapy for prostate cancer~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~Other~* No concurrent soy supplements~* No concurrent foods high in genistein~* No concurrent active therapy for neoplastic disorders

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
- Group B (Type: EXPERIMENTAL): Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).